Porse B T, Cundliffe E, Garrett R A
RNA Regulation Centre Institute of Molecular Biology, University of Copenhagen, Solvgade 83H, Copenhagen K, DK1307, Denmark.
J Mol Biol. 1999 Mar 19;287(1):33-45. doi: 10.1006/jmbi.1999.2600.
Micrococcin-resistant mutants of Bacillus megaterium that carry mutations affecting ribosomal protein L11 have been characterised. The mutants fall into two groups. "L11-minus" strains containing an L11 gene with deletions, insertions or nonsense mutations which grow 2.5-fold slower than the wild-type strain, whereas other mutants carrying single-site substitutions within an 11 amino acid residue segment of the N-terminal domain of L11 grow normally. Protein L11 binds to 23 S rRNA within the ribosomal GTPase centre which regulates GTP hydrolysis on ribosomal factors. Micrococcin binding within the rRNA component of this centre was probed on wild-type and mutant ribosomes, in vivo, using dimethyl sulphate where it generated an rRNA footprint indistinguishable from that produced in vitro, even after the cell growth had been arrested by treatment with either kirromycin or fusidic acid. No drug-rRNA binding was detected in vivo for the L11-minus mutants, while reduced binding (approximately 30-fold) was observed for two single-site mutants P23L and P26L. For the latter, the reduced drug affinity alone did not account for the resistance-phenotype because rapid cell growth occurred even at drug concentrations that would saturate the ribosomes. Micrococcin was also bound to complexes containing an rRNA fragment and wild-type or mutant L11, expressed as fusion proteins, and they were probed with proteinases. The drug produced strong protection effects on the wild-type protein and weak effects on the P23L and P26L mutant proteins. We infer that inhibition of cell growth by micrococcin, as for thiostrepton, results from the imposition of a conformational constraint on protein L11 which, in turn, perturbs the function(s) of the ribosomal factor-guanosine nucleotide complexes.
已对携带影响核糖体蛋白L11突变的巨大芽孢杆菌耐微球菌素突变体进行了表征。这些突变体分为两组。“L11缺失”菌株含有具有缺失、插入或无义突变的L11基因,其生长速度比野生型菌株慢2.5倍,而其他在L11 N端结构域的11个氨基酸残基片段内携带单点取代的突变体生长正常。蛋白L11与核糖体GTPase中心内的23 S rRNA结合,该中心调节核糖体因子上的GTP水解。在野生型和突变核糖体上,在体内使用硫酸二甲酯探测该中心rRNA组分内的微球菌素结合情况,即使在用奇霉素或夫西地酸处理使细胞生长停滞之后,其产生的rRNA足迹与体外产生的足迹无法区分。在体内未检测到L11缺失突变体的药物-rRNA结合,而对于两个单点突变体P23L和P26L,观察到结合减少(约为30倍)。对于后者,单独的药物亲和力降低并不能解释抗性表型,因为即使在使核糖体饱和的药物浓度下也会发生快速细胞生长。微球菌素也与含有rRNA片段和野生型或突变型L11的复合物结合,这些复合物以融合蛋白形式表达,并用蛋白酶进行探测。该药物对野生型蛋白产生强烈的保护作用,并对P